Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Michael David Garrison, Executive Vice President and President of the Medical (TASE:BLWV) segment at Becton Dickinson & Co. (NYSE:BDX), recently sold shares of the company in a transaction dated April 9, 2025. According to a filing with the Securities and Exchange Commission, Garrison sold 479 shares of common stock at a price of $197.28 per share, amounting to a total transaction value of $94,497.
Following this sale, Garrison retains ownership of 4,887 shares in the company. The transaction was executed under a Rule 10b5-1 trading plan that Garrison adopted on August 2, 2024.
In other recent news, BD (Becton, Dickinson and Company) announced the separation of its Biosciences and Diagnostic Solutions business, a move aimed at enhancing strategic focus and growth-oriented investments for both BD and the newly independent entity. This decision follows a comprehensive business portfolio evaluation and is expected to unlock significant potential value for stakeholders. Additionally, BD has initiated a clinical trial for its GalaFLEX LITE™ Scaffold, a device designed to reduce capsular contracture recurrence in breast revision surgeries, marking a step towards obtaining FDA Premarket Approval.
The company also appointed Gregory J. Hayes to its board of directors, bringing his extensive experience in mergers and corporate strategy to BD's ongoing transformation efforts. In another development, activist investor Starboard Value has acquired a stake in BD, reportedly advocating for the sale of the company’s life sciences division, although the size of the stake remains undisclosed. Meanwhile, BD shareholders have approved all board nominees and the appointment of Ernst & Young as the independent auditor for the fiscal year 2025.
These developments reflect BD's ongoing efforts to streamline operations and enhance corporate governance. The company remains focused on innovation and strategic growth, as evidenced by its recent moves in clinical trials and board appointments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.